GSE200538
Transcriptome sequencing of HepG2 cells upon treatment of Butyrolactone I (PQY09) or derivatives (PQY23_1) butenolide compounds for exploring the targets of PQYs to further study the pharmacological activities
Transcriptome sequencing (RNA-Seq) of HepG2 cells upon treatment of the 50µM Butyrolactone I (PQY09) or derivatives (PQY23_1) butenolide compounds isolated from marine-derived fungi or DMSO(0.1%) as blank contrast for exploring the targets of PQYs to further study the pharmacological activities Butenolide, a mycotoxin produced by several toxigenic Fusarium species, fre-quently invades many important grains, and evokes a broad spectrum of toxic effects. But several butenolide derivatives, especially the well-known compound butyrolactone I, have been reported to show diverse biological activities, including an-ti-inflammatory , antibacterial , antiviral, antitumor, and a-/ß-glucosidase inhibitory activities. So in order to investigate the other effect of PQYs and toxicity target, we  used the second-generation transcriptome sequencing(RNA-seq) to determine the expression changes of each gene in HepG2 cells. Overall design: mRNA profiles of  HepG2 cells upon treatment of the 50µM PQY09 or PQY23_1 or DMSO(0.1%) were generated by deep sequencing, using illumina Novaseq™ 6000